Condition: Acute Kidney Injury · Sponsor: Talphera, Inc
A prospective, randomized, placebo-controlled clinical study to investigate the safety and efficacy of Niyad (nafamostat mesylate) for anticoagulation of extracorporeal blood circulating through a dialysis filter in patients undergoing CRRT who cannot tolerate heparin or are at higher risk for bleeding.
This description comes directly from the study's public registry record.
Nazneen Patel · 647-724-5709 · nazneen.patel@clinchoice.com
Chris Houchins · chris.houchins@clinchoice.com
Always discuss trial participation with your own doctor first.
| University of California Los Angeles | Los Angeles, California, United States | Recruiting |
| AdventHealth | Orlando, Florida, United States | Not Yet Recruiting |
| Henry Ford Health | Detroit, Michigan, United States | Recruiting |
| University of New Mexico | Albuquerque, New Mexico, United States | Recruiting |
| Northwell Health | Great Neck, New York, United States | Recruiting |
| Mount Sinai | New York, New York, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
| University of Pittsburgh Medical Center | Pittsburgh, Pennsylvania, United States | Recruiting |
| Medical University of South Carolina | Charleston, South Carolina, United States | Recruiting |
| Baylor University Medical Center | Dallas, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06150742